ReviewNeoplasia (New York, N.Y.)1999
HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part II. Vector systems and applications.
Review in Neoplasia (New York, N.Y.), 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 72 citations in OpenAlex.
- Imaging in gene therapy of patients with glioma.Journal of neuro-oncology · 2003Trial
- Biosafety and efficacy of Kv7 activating rdHSV-CA8∗ analgesic gene therapy for chronic pain via the intra-articular route in mice.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- A Review on the Stability Challenges of Advanced Biologic Therapeutics.Pharmaceutics · 2025Review
- Herpes Simplex Oncolytic Viral Therapy for Malignant Glioma and Mechanisms of Delivery.World neurosurgery · 2025Review
- Novel Gene Therapy Approaches for Targeting Neurodegenerative Disorders: Focusing on Delivering Neurotrophic Genes.Molecular neurobiology · 2025Review
- Induced Pluripotent Stem Cells (iPSCs) and Gene Therapy: A New Era for the Treatment of Neurological Diseases.International journal of molecular sciences · 2021Review
- Improvement of HSV-1 based amplicon vectors for a safe and long-lasting gene therapy in non-replicating cells.Molecular therapy. Methods & clinical development · 2021Article
- Viral tools for neuroscience.Nature reviews. Neuroscience · 2020Review
- Article
- Glioblastoma multiforme: State of the art and future therapeutics.Surgical neurology international · 2014Review
- Evaluation and optimization of the administration of a selectively replicating herpes simplex viral vector to the brain by convection-enhanced delivery.Cancer gene therapy · 2011Article
- Gene therapy approaches for stem cell protection.Gene therapy · 2008Review
- Human gene therapy and imaging in neurological diseases.European journal of nuclear medicine and molecular imaging · 2005Review
- Potential of equine herpesvirus 1 as a vector for immunization.Journal of virology · 2005Article
- Variability in infectivity of primary cell cultures of human brain tumors with HSV-1 amplicon vectors.Gene therapy · 2005Article
- Human cytomegalovirus plasmid-based amplicon vector system for gene therapy.Genetic vaccines and therapy · 2005Article
- Molecular imaging of gene therapy for cancer.Gene therapy · 2004Review
- PET-based molecular imaging in neuroscience.European journal of nuclear medicine and molecular imaging · 2003Review
- Potential new methods for antiepileptic drug delivery.CNS drugs · 2002Review
- Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors.Proceedings of the National Academy of Sciences of the United States of America · 2001Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Many properties of HSV-1 are especially suitable for using this virus as a vector to treat diseases affecting the central nervous system (CNS), such as Parkinson's disease or malignant gliomas. These advantageous properties include natural neurotropism, high transduction efficiency, large transgene capacity, and the ability of entering a latent state in neurons. Selective oncolysis in combination with modulation of the immune response mediated by replication-conditional HSV-1 vectors appears to be a highly promising approach in the battle against malignant glioma. Helper virus-free HSV/AAV hybrid amplicon vectors have great promise in mediating long-term gene expression in the PNS and CNS for the treatment of various neurodegenerative disorders or chronic pain. Current research focuses on the design of HSV-1-derived vectors which are targeted to certain cell types and support transcriptionally regulatable transgene expression. Here, we review the recent developments on HSV-1-based vector systems and their applications in experimental and clinical gene therapy protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.